A069620 Stock Overview
Manufactures and sells pharmaceutical products in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A069620 from our risk checks.
Daewoong Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩130,000.00 |
| 52 Week High | ₩133,800.00 |
| 52 Week Low | ₩96,600.00 |
| Beta | 0.81 |
| 11 Month Change | 29.22% |
| 3 Month Change | 15.35% |
| 1 Year Change | 30.92% |
| 33 Year Change | -23.98% |
| 5 Year Change | -16.40% |
| Change since IPO | 981.72% |
Recent News & Updates
Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings
Jul 24
We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt
Jul 04Shareholder Returns
| A069620 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 10.0% | -1.5% | -4.0% |
| 1Y | 30.9% | 14.8% | 2.2% |
Return vs Industry: A069620 exceeded the KR Pharmaceuticals industry which returned 14.8% over the past year.
Return vs Market: A069620 exceeded the KR Market which returned 2.2% over the past year.
Price Volatility
| A069620 volatility | |
|---|---|
| A069620 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A069620 has not had significant price volatility in the past 3 months.
Volatility Over Time: A069620's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 1,679 | Shawn Park | www.daewoong.com |
Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices.
Daewoong Pharmaceutical Co., Ltd Fundamentals Summary
| A069620 fundamental statistics | |
|---|---|
| Market cap | ₩1.50t |
| Earnings (TTM) | ₩114.47b |
| Revenue (TTM) | ₩1.39t |
13.1x
P/E Ratio1.1x
P/S RatioIs A069620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A069620 income statement (TTM) | |
|---|---|
| Revenue | ₩1.39t |
| Cost of Revenue | ₩689.63b |
| Gross Profit | ₩699.07b |
| Other Expenses | ₩584.60b |
| Earnings | ₩114.47b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.95k |
| Gross Margin | 50.34% |
| Net Profit Margin | 8.24% |
| Debt/Equity Ratio | 50.8% |
How did A069620 perform over the long term?
See historical performance and comparison